Case study: High-throughput expression of SARS-CoV-2 viral antigens

Customer problem

Replacement for costly and inefficient mammalian (CHO, HEK) cell production of SARS-CoV-2 “Spike” receptor binding domain (RBD) variants required for protein subunit vaccine

Ingenza solution

Proprietary P. pastoris strains secreting RBD (COVID-19) vaccine components
Viable upstream/downstream manufacture and conjugation to subunit vaccine carrier
Highly cost-competitive with CHO, HEK manufacture and identical immunogenic performance

Host

P. pastoris secreting SARS-CoV-2 RBD variants of concern

Build & Screen

Design and integration of genetic constructs
FACS supported visABLE^® screening for jackpot clones with optimal productivity/stability

Pre-clinical performance

Highly immunogenic performance confirmed
Progressed to pre-clinical animal testing

Want to Know More?

We’d love to hear from you.

Contact Us